Rankings
▼
Calendar
BCRX Q1 2024 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
BCRX
BioCryst Pharmaceuticals, Inc.
$2B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$93M
+34.9% YoY
Gross Profit
$91M
98.6% margin
Operating Income
-$14M
-15.6% margin
Net Income
-$35M
-38.1% margin
EPS (Diluted)
$-0.17
QoQ Revenue Growth
-0.7%
Cash Flow
Operating Cash Flow
-$54M
Free Cash Flow
-$54M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$468M
Total Liabilities
$944M
Stockholders' Equity
-$476M
Cash & Equivalents
$84M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$93M
$69M
+34.9%
Gross Profit
$91M
$68M
+34.9%
Operating Income
-$14M
-$28M
+49.0%
Net Income
-$35M
-$53M
+33.7%
Revenue Segments
Product
$89M
96%
Collaborative and Other Research and Development
$3M
4%
← FY 2024
All Quarters
Q2 2024 →